ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.58
-0.50%
US Tech 100
18,385.60
0.37%
S&P 500
5,306.04
0.02%
US Dollar vs CAD
1.36465
0.12%
Bitcoin
68,451.88
-1.36%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Innate Pharma SA (IPHA)

  7. Innate Pharma SA (IPHA) News

IPHA

Innate Pharma (IPHA)

Innate Pharma SA
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IPHA
DateTimeSourceHeadlineSymbolCompany
05/28/20245:03AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
05/28/202412:00AMBusiness WireInnate Pharma annonce sa participation à de prochaines conférences investisseursNASDAQ:IPHAInnate Pharma SA
05/28/202412:00AMBusiness WireInnate Pharma Announces Its Participation in Upcoming Investor ConferencesNASDAQ:IPHAInnate Pharma SA
05/24/20245:35AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
05/24/202412:00AMBusiness WireInnate Pharma partage les abstracts sélectionnés pour le congres annuel de l’ASCO 2024NASDAQ:IPHAInnate Pharma SA
05/24/202412:00AMBusiness WireInnate Pharma Highlights Abstracts Selected for ASCO 2024 Annual MeetingNASDAQ:IPHAInnate Pharma SA
05/23/20243:00PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
05/23/20243:00PMBusiness WireOutcome of Innate Pharma’s 2024 Annual General MeetingNASDAQ:IPHAInnate Pharma SA
05/23/20243:00PMBusiness WireRésultats de l’Assemblée Générale mixte du 23 mai 2024NASDAQ:IPHAInnate Pharma SA
05/21/202412:00AMBusiness WireInnate Pharma: Clarification Regarding SAR443579 DesignationNASDAQ:IPHAInnate Pharma SA
05/21/202412:00AMBusiness WireInnate Pharma: Clarification concernant le statut de SAR443579NASDAQ:IPHAInnate Pharma SA
05/15/20245:01AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
05/15/202412:00AMBusiness WireInnate Pharma partage les abstracts sélectionnés pour le congrès 2024 de l’EHANASDAQ:IPHAInnate Pharma SA
05/15/202412:00AMBusiness WireInnate Pharma Highlights Abstracts Selected for EHA 2024 CongressNASDAQ:IPHAInnate Pharma SA
05/14/202412:00AMBusiness WireInnate Pharma Reports First Quarter 2024 Business Update and Financial ResultsNASDAQ:IPHAInnate Pharma SA
05/14/202412:00AMBusiness WireInnate Pharma fait le point sur ses activités et publie ses résultats financiers pour le premier trimestre 2024NASDAQ:IPHAInnate Pharma SA
05/07/202412:00AMBusiness WireInnate Pharma Announces Conference Call and Webcast for Q1 2024 Business UpdateNASDAQ:IPHAInnate Pharma SA
05/07/202412:00AMBusiness WireInnate Pharma organise une conférence téléphonique pour présenter ses résultats au premier trimestre 2024NASDAQ:IPHAInnate Pharma SA
04/15/202412:00AMBusiness WireInnate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024NASDAQ:IPHAInnate Pharma SA
04/15/202412:00AMBusiness WireInnate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer PatientsNASDAQ:IPHAInnate Pharma SA
04/15/202412:00AMBusiness WireL’Assemblée Générale d’Innate Pharma aura lieu le 23 mai 2024NASDAQ:IPHAInnate Pharma SA
04/15/202412:00AMBusiness WireInnate Pharma annonce la progression de l’essai clinique évaluant le NK Cell Engager SAR443579 / IPH6101 développé par Sanofi vers la Phase 2 dans divers cancers du sangNASDAQ:IPHAInnate Pharma SA
04/10/202412:00AMBusiness WireInnate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug ConjugateNASDAQ:IPHAInnate Pharma SA
04/10/202412:00AMBusiness WireInnate Pharma présente des données d’efficacité précliniques pour IPH45, son conjugué anticorps-médicament innovant ciblant nectine-4 a l’AACR 2024NASDAQ:IPHAInnate Pharma SA
04/09/202412:00AMBusiness WireInnate Pharma annonce sa participation à une prochaine Conférence InvestisseursNASDAQ:IPHAInnate Pharma SA
04/09/202412:00AMBusiness WireInnate Pharma Announces Its Participation in Upcoming Investor ConferenceNASDAQ:IPHAInnate Pharma SA
04/05/20242:34AMBusiness WireInnate Pharma publie son Document D’enregistrement Universel 2023 et son Rapport Annuel 2023 sur « Form 20-F »NASDAQ:IPHAInnate Pharma SA
04/05/20242:34AMBusiness WireInnate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-FNASDAQ:IPHAInnate Pharma SA
03/21/20241:00AMBusiness WireInnate Pharma présente ses résultats financiers et l'avancée de son portefeuille pour l'année 2023NASDAQ:IPHAInnate Pharma SA
03/21/20241:00AMBusiness WireInnate Pharma Reports Full Year 2023 Financial Results and Business UpdateNASDAQ:IPHAInnate Pharma SA
 Showing the most relevant articles for your search:NASDAQ:IPHA

Your Recent History

ASX
CKFAK
BIT
UB5178
Unicredit Bank
USOTC
TSLTF
TransAlta (PK)
USOTC
SLYIU
Sealy Industrial Partner... (GM)
EU
A872T
A872T
BIT
UR9ZMN
UniCredit Bank
NYSE
SAIC
Science Applications
TSXV
JADE
Jade Leader
LSE
V3EL
Vanesgdeud
BIT
UB93BV
Unicredit Bank
BIT
UR9ZP1
UniCredit Bank
TIDE
BCHBTC
Bitcoin Cash
ASX
VRS
Veris
USOTC
SNEHF
Snack Empire (PK)
USOTC
PASMF
Premier Asset Management (PK)
GATE
COREUMUSDT
Coreum
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved